Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines

International Journal of Cancer

Volumn 131, Issue 9, 2012, Pages 1998-2007

  Van Agthoven, Ton ^a   Godinho, Marcia F E ^a   Wulfkuhle, Julia D ^b   Petricoin III, Emanuel F ^b   Dorssers, Lambert C J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

AKT; BCAR1; BCAR3; BCAR4; EGFR; phosphorylation; signaling pathway; tamoxifen resistance

Indexed keywords

BCAR3 PROTEIN; BCAR4 PROTEIN; CRK ASSOCIATED SUBSTRATE PROTEIN; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN HRAS; PROTEIN KINASE B; PROTEIN SHC; PROTIEN HEF1; PROTIEN MCF7; STAT5 PROTEIN; STAT6 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BCAR GENE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME SUBSTRATE; GENE ACTIVATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CRK-ASSOCIATED SUBSTRATE PROTEIN; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SHC SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84865558963     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27489     Document Type: Article

References (55)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN,. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
3. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study II. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82. (Pubitemid 47073490)
4. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LCJ,. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 27: 542-9.
5. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH,. Pathways to tamoxifen resistance. Cancer Lett 2007; 256: 1-24. (Pubitemid 47333324)
6. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R,. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-61. (Pubitemid 36395255)
7. Osborne CK, Shou J, Massarweh S, Schiff R,. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s. (Pubitemid 40111098)
8. Clarke R, Leonessa F, Welch JN, Skaar TC,. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53: 25-71. (Pubitemid 32173107)
9. Van Agthoven T, Van Agthoven TLA, Dekker A, Foekens JA, Dorssers LCJ,. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 1994; 8: 1474-83. (Pubitemid 24370196)
10. Dorssers LCJ, Van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM,. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993; 7: 870-8. (Pubitemid 23220637)
11. Meijer D, Van Agthoven T, Bosma PT, Nooter K, Dorssers LCJ,. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 2006; 4: 379-86. (Pubitemid 44035157)
12. Van Agthoven T, Veldscholte J, Smid M, Van Agthoven TLA, Vreede L, Broertjes M, De Vries I, De Jong D, Sarwari R, Dorssers LCJ,. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009; 114: 23-30.
13. Dorssers LCJ, Grebenchtchikov N, Brinkman A, Look MP, Van Broekhoven SPJ, De Jong D, Peters HA, Portengen H, Meijer-Van Gelder ME, Klijn JGM, Van Tienoven TH, Geurts-Moespot A, et al. The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 2004; 10: 6194-202. (Pubitemid 39287526)
14. Meijer D, Sieuwerts AM, Look MP, Van Agthoven T, Foekens JA, Dorssers LCJ,. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008; 15: 101-11. (Pubitemid 351449731)
15. van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC,. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer 2009; 101: 1824-32.
16. Godinho MFE, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LCJ, van Agthoven T,. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer 2010; 103: 1284-91.
17. Van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, Van Agthoven TLA, Sarwari R, Sleijfer S, Foekens JA, Dorssers LCJ,. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 2010; 17: 215-30.
18. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA,. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-9. (Pubitemid 32458030)
19. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008; 7: 1508-17.
20. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, III, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4: 346-55. (Pubitemid 40590555)
21. Dorssers LCJ, Van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ,. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor pathway. Breast Cancer Res 2005; 7: R82-R92.
22. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ,. BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000; 92: 112-20. (Pubitemid 30089867)
23. Van Agthoven T, Van Agthoven TLA, Dekker A, Van der Spek PJ, Vreede L, Dorssers LCJ,. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 1998; 17: 2799-808. (Pubitemid 28227126)
24. Van Agthoven T, Van Agthoven TLA, Portengen H, Foekens JA, Dorssers LCJ,. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 1992; 52: 5082-88.
25. Brinkman A, De Jong D, Tuinman S, Azaouagh N, Van Agthoven T, Dorssers LCJ,. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res Treat 2010; 120: 401-8.
26. Van Agthoven T, Timmermans M, Foekens JA, Dorssers LCJ, Henzen-Logmans SC,. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994; 144: 1238-46. (Pubitemid 24172086)
27. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC,. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 1997; 57: 3723-7. (Pubitemid 27381215)
28. Barone I, Brusco L, Fuqua SA,. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010; 16: 2702-8.
29. Roodi N, Bailey LR, Kao W-Y, Verrier CS, Yee CJ, Dupont WD, Parl FF,. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995; 87: 446-51.
30. Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven TV,. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol 2011; 226: 1741-9.
31. Hunter T, Pines J,. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82. (Pubitemid 24363801)
32. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I,. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61: 8452-8. (Pubitemid 33131124)
33. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54. (Pubitemid 40637826)
34. Manning BD, Cantley LC,. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74. (Pubitemid 46962095)
35. Cai D, Iyer A, Felekkis KN, Near RI, Luo Z, Chernoff J, Albanese C, Pestell RG, Lerner A,. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res 2003; 63: 6802-8. (Pubitemid 37322962)
36. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM,. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139-46. (Pubitemid 41404144)
37. Yu H, Jove R,. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)
38. Van der Flier S, Chan CMW, Brinkman A, Smid M, Johnston SRD, Dorssers LCJ, Dowsett M,. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 2000; 89: 465-8.
39. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 2006; 66: 4672-80.
40. Tikhmyanova N, Little JL, Golemis EA,. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 2010; 67: 1025-48.
41. Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH,. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 2007; 67: 6174-82. (Pubitemid 47037498)
42. Makkinje A, Near RI, Infusini G, Vanden Borre P, Bloom A, Cai D, Costello CE, Lerner A,. AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern. Cell Signal 2009; 21: 1423-35.
43. Lu Y, Brush J, Stewart TA,. NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway. J Biol Chem 1999; 274: 10047-52.
44. Cai D, Clayton LK, Smolyar A, Lerner A,. AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines. J Immunol 1999; 163: 2104-12. (Pubitemid 29382216)
45. Vervoort VS, Roselli S, Oshima RG, Pasquale EB,. Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling. Gene 2007; 391: 161-70. (Pubitemid 46356795)
46. Sakakibara A, Ohba Y, Kurokawa K, Matsuda M, Hattori S,. Novel function of Chat in controlling cell adhesion via Cas-Crk-C3G-pathway-mediated Rap1 activation. J Cell Sci 2002; 115: 4915-24. (Pubitemid 36054643)
47. Near RI, Zhang Y, Makkinje A, Vanden Borre P, Lerner A,. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. J Cell Physiol 2007; 212: 655-65. (Pubitemid 47267535)
48. Defilippi P, Di Stefano P, Cabodi S,. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006; 16: 257-63. (Pubitemid 43728873)
49. Vanden Borre P, Near RI, Makkinje A, Mostoslavsky G, Lerner A,. BCAR3/AND-34 can signal independent of complex formation with CAS family members or the presence of p130Cas. Cell Signal 2011; 23: 1030-40.
50. Keefe DM, Bateman EH,. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2011; 9: 98-109.
51. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE,. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005; 7: R796-R807.
52. Miller TW, Rexer BN, Garrett JT, Arteaga CL,. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13: 224.
53. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007; 6: 820-32. (Pubitemid 46554552)
54. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, Munson PJ, Petricoin E, III, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003; 100: 14229-34. (Pubitemid 37499219)
55. Calvo KR, Liotta LA, Petricoin EF,. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 2005; 25: 107-25. (Pubitemid 41437713)